Skip to main content

Advertisement

Log in

Update on Cytomegalovirus Infections of the Gastrointestinal System in Solid Organ Transplant Recipients

  • Intra-abdominal Infections, Hepatitis, and Gastroenteritis (DA Bobak, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Cytomegalovirus (CMV) infection of the gastrointestinal tract is the most common manifestation of tissue-invasive CMV disease, and is a significant cause of morbidity and mortality in the solid organ transplantation (SOT) recipient. In addition to the direct effects of the infection, its indirect effects on allograft function, risk for other opportunistic infections, and mortality are significant in this population. The most common clinical syndromes are esophagitis, colitis, and hepatitis; however, infection can occur anywhere in the gastrointestinal tract. Diagnosis is usually by histopathology or viral culture of tissue specimens; molecular assays also often have a role. Antivirals are the cornerstone of therapy for gastrointestinal tract CMV disease and complications such as recurrent infection and antiviral resistance are not uncommon. Prevention with antiviral prophylaxis or preemptive therapy is important. This review summarizes recent data regarding the clinical manifestations, diagnosis, treatment, and prevention of gastrointestinal tract CMV infection in the SOT population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Eid AJ, Razonable RR: New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010, 70:965–981. Excellent review of recent management issues in CMV infection after SOT

    Article  PubMed  CAS  Google Scholar 

  2. Loewendorf A, Benedict CA. Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. J Intern Med. 2010;267:483–501.

    Article  PubMed  CAS  Google Scholar 

  3. Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol. 2010;6:711–21.

    Article  PubMed  Google Scholar 

  4. Ozdemir FN, Akgul A, Altunoglu A, et al. The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients. Transplant Proc. 2007;39:990–2.

    Article  PubMed  CAS  Google Scholar 

  5. Rodrigo E, Fernandez-Fresnedo G, Valero R, et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol. 2006;17 Suppl 3:S291–5.

    Article  PubMed  Google Scholar 

  6. Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation. 2006;82(2 Suppl):S15–7.

    Article  PubMed  Google Scholar 

  7. Bobak DA. Gastrointestinal infections caused by cytomegalovirus. Curr Infect Dis Rep. 2003;5:101–7.

    Article  PubMed  Google Scholar 

  8. Trappe R, Pohl H, Forberger A, et al. Acute esophageal necrosis (black esophagus) in the renal transplant recipient: manifestation of primary cytomegalovirus infection. Transpl Infect Dis. 2007;9:42–5.

    Article  PubMed  CAS  Google Scholar 

  9. Harada N, Shimada M, Suehiro T, et al. Unusual endoscopic findings of CMV esophagitis after liver transplantation. Hepatogastroenterology. 2005;52:1236–9.

    PubMed  Google Scholar 

  10. Li W, Fan H, Yiping L. Postural epigastric pain as a sign of cytomegalovirus gastritis in renal transplant recipients: a case-based review. Transplant Proc. 2009;41:3956–8.

    Article  PubMed  CAS  Google Scholar 

  11. Llado L, Castellote J, Fabregat J, et al. Antral mass due to cytomegalovirus infection requiring gastrectomy in a liver transplant recipient. Transpl Infect Dis. 2008;10:354–7.

    Article  PubMed  CAS  Google Scholar 

  12. Talmon GA. Histologic features of cytomegalovirus enteritis in small bowel allografts. Transplant Proc. 2010;42:2671–5.

    Article  PubMed  CAS  Google Scholar 

  13. Petrilsi E, Chiereghin A, Gabrielli L, et al. Early and late virologic monitoring of cytomegalovirus, Epstein-Barr virus, and human herpes virus 6 infections in small bowel/multivisceral transplant recipients. Transplant Proc. 2010;42:74–8.

    Article  Google Scholar 

  14. Navaneethan U, Venkatesh PG, Wang J. Cytomegalovirus ileitis in a patient after liver transplantation- differentiating from de novo IBD. J Crohns Colitis. 2011;5:354–9.

    Article  PubMed  Google Scholar 

  15. Dahman M, Krell R, Brayman K, et al. Simultaneous Clostridium difficile-associated colitis and late-onset intestinal cytomegalovirus disease in a renal transplant recipient. Ann Transplant. 2010;15:72–6.

    PubMed  Google Scholar 

  16. Veroux M, Puzzo L, Corona D, et al. Cytomegalovirus and Clostridium difficile ischemic colitis in a renal transplant recipient: a lethal complication of anti-rejection therapy? Urol Int. 2007;79:177–9.

    Article  PubMed  Google Scholar 

  17. Hampton DD, Poleski MH, Onken JE. Inflammatory bowel disease following solid organ transplantation. Clin Immunol. 2008;128:287–93.

    Article  PubMed  CAS  Google Scholar 

  18. Verdonk RC, Haagsma EB, Van Den Berg AP, et al. Inflammatory bowel disease after liver transplantation: a role for cytomegalovirus infection. Scand J Gastroenterol. 2006;41:205–11.

    Article  PubMed  Google Scholar 

  19. Lee SO, Razonable RR. Current concepts on cytomegalovirus infection after liver transplantation. World J Hepatol. 2010;2:325–36.

    Article  PubMed  Google Scholar 

  20. Demetris AJ. Evolution of hepatitis C in liver allografts. Liver Transpl. 2009;15 Suppl 2:S35–41.

    Article  PubMed  Google Scholar 

  21. Ramirez S, Perez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C recurrence. Liver Transpl. 2008;14 Suppl 2:S27–35.

    Article  PubMed  Google Scholar 

  22. Razonable RR, Burak KW, van Cruijsen H, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis. 2002;35:974–81.

    Article  PubMed  Google Scholar 

  23. Drage M, Reid A, Callaghan CJ, et al. Acute cytomegalovirus cholecystitis following renal transplantation. Am J Transplant. 2009;9:1249–52.

    Article  PubMed  CAS  Google Scholar 

  24. Baroco AL, Oldfield EC. Gastrointestinal cytomegalovirus disease in the immunocompromised patient. Curr Gastroenterol Rep. 2008;10:409–16.

    Article  PubMed  Google Scholar 

  25. Kamalkumar BS, Agarwal SK, Garg P, et al. Acute pancreatitis with CMV papillitis and cholangiopathy in a renal transplant recipient. Clin Exp Nephrol. 2009;13:389–91.

    Article  PubMed  Google Scholar 

  26. Klassen DK, Drachenberg CB, Papadimitriou JC, et al. CMV allograft pancreatitis: diagnosis, treatment, and histological features. Transplantation. 2000;69:1968–71.

    Article  PubMed  CAS  Google Scholar 

  27. ••Kotton CN, Kumar D, Caliendo AM, et al.: International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010, 89:779–795. Recent international consensus guidelines with extensive review of the literature by international transplant experts on management of CMV in SOT

    Article  PubMed  Google Scholar 

  28. Halme L, Lempinen M, Arola J, et al. High frequency of gastroduodenal cytomegalovirus infection in liver transplant patients. APMIS. 2008;116:99–106.

    Article  PubMed  Google Scholar 

  29. •Grim SA, Pereira E, Guzman G, et al.: CMV PCR as a diagnostic tool for CMV gastrointestinal disease after solid organ transplantation. Transplantation 2010, 90:799–801. Overview of recent available data on use of molecular assays for diagnosis of gastrointestinal tract disease in SOT

    Article  PubMed  Google Scholar 

  30. Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2008;22:162–70.

    Article  PubMed  Google Scholar 

  31. Halme L, Hockerstedt K, Samela K, et al. CMV infection detected in the upper gastrointestinal tract after liver transplantation. Transpl Int. 1998;11 Suppl 1:S242–4.

    PubMed  Google Scholar 

  32. Jang EY, Park SY, Lee EJ, et al. Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. Clin Infect Dis. 2009;48:e121–4.

    Article  PubMed  Google Scholar 

  33. Fica A, Cervera C, Perez N, et al. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests. Transpl Infect Dis. 2007;9:203–10.

    Article  PubMed  CAS  Google Scholar 

  34. Ganzenmueller T, Henke-Gendo C, Schlue J, et al. Quantification of cytomegalovirus DNA levels in intestinal biopsies as a diagnostic tool for CMV intestinal disease. J Clin Virol. 2009;46:254–8.

    Article  PubMed  CAS  Google Scholar 

  35. Muir SW, Murray J, Farquharson MA, et al. Detection of cytomegalovirus in upper gastrointestinal biopsies from heart transplant recipients: comparison of light microscopy, immunocytochemistry, in situ hybridisation, and nested PCR. J Clin Pathol. 1998;51:807–11.

    Article  PubMed  CAS  Google Scholar 

  36. Brainard JA, Greenson JK, Vesy CJ, et al. Detection of cytomegalovirus in liver transplant biopsies. A comparison of light microscopy, immunohistochemistry, duplex PCR and nested PCR. Transplantation. 1994;57:1753–7.

    PubMed  CAS  Google Scholar 

  37. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S78–86.

    Article  PubMed  Google Scholar 

  38. Asberg A, Humar A, Rollaq H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7:2106–13.

    Article  PubMed  CAS  Google Scholar 

  39. •Eid AJ, Arthurs SK, Deziel PJ et al.: Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transpl 2010, 10:157–161. Study of clinical risk factors for relapse of gastrointestinal CMV disease in SOT recipients

    Article  CAS  Google Scholar 

  40. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002;35:866–72.

    Article  PubMed  CAS  Google Scholar 

  41. Li F, Kenyon KW, Kirby KA, et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis. 2007;45:439–47.

    Article  PubMed  CAS  Google Scholar 

  42. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356:645–9.

    Article  PubMed  CAS  Google Scholar 

  43. Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant. 2002;21:1274–82.

    Article  PubMed  Google Scholar 

  44. Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis. 2002;185:20–7.

    Article  PubMed  CAS  Google Scholar 

  45. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis. 2004;189:1615–8.

    Article  PubMed  CAS  Google Scholar 

  46. •Myhre HA, Haug Dorenberg D, Kristiansen KI, et al.: Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 2011, 92:217–223. Largest outcome study to date of ganciclovir-resistant CMV infections in SOT recipients

    Article  PubMed  CAS  Google Scholar 

  47. Boivin G, Goyette N, Rollaq H, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther. 2009;14:697–704.

    PubMed  Google Scholar 

  48. Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother. 2010;65:2628–40.

    Article  PubMed  CAS  Google Scholar 

  49. •Drew WL: Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clin Infect Dis 2010, 50:733–736. Concise review of CMV resistance testing

    Article  PubMed  CAS  Google Scholar 

  50. West P, Schmiedeskamp M, Neeley H, et al. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL 97 mutation. Transpl Infect Dis. 2008;10:129–32.

    Article  PubMed  CAS  Google Scholar 

  51. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010;12:489–96.

    Article  PubMed  CAS  Google Scholar 

  52. Snydman DR. Leflunomide: a small step forward in meeting the urgent need for treatment of drug-resistant cytomegalovirus infection. Transplantation. 2010;90:362–3.

    Article  PubMed  CAS  Google Scholar 

  53. Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis. 2008;46:1455–7.

    Article  PubMed  CAS  Google Scholar 

  54. Dropulic LK, Cohen JI. Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Clin Pharmacol Ther. 2010;88:610–9.

    Article  PubMed  CAS  Google Scholar 

  55. Avery RK. Update in the management of ganciclovir-resistant cytomegalovirus infection. Curr Opin Infect Dis. 2008;21:433–7.

    Article  PubMed  Google Scholar 

  56. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008;8:975–83.

    Article  PubMed  CAS  Google Scholar 

  57. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143:870–80.

    PubMed  Google Scholar 

  58. Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8:69–77.

    PubMed  CAS  Google Scholar 

  59. •Humar A, Lebranchu Y, Vincenti F, et al.: The efficacy and safety of 200 days of valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010, 10:1228–1237. Important efficacy study of extended duration valganciclovir prophylaxis in D+/R- kidney transplant recipients in decreasing incidence of CMV disease

    Article  PubMed  CAS  Google Scholar 

  60. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis. 2008;46:840–6.

    Article  PubMed  Google Scholar 

  61. Boudreault AA, Xie H, Rakita RM, et al. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis. Transpl Infect Dis. 2011;13:244–9.

    Article  PubMed  CAS  Google Scholar 

  62. Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, et al. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J Heart Lung Transplant. 2007;26:1019–24.

    Article  PubMed  Google Scholar 

  63. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis. 2001;184:1461–4.

    Article  PubMed  CAS  Google Scholar 

  64. •Humar A, Limaye AP, Blumberg EA, et al.: Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010, 90:1427–1431. Follow-up 2 year results of efficacy study of extended duration valganciclovir prophylaxis in D+/R- kidney transplant recipients showing long-term reduction in CMV disease

    Article  PubMed  CAS  Google Scholar 

  65. Walker JK, Scholz LM, Scheetz MN, et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation. 2007;83:874–82.

    Article  PubMed  CAS  Google Scholar 

  66. Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis. 2003;187:1801–8.

    Article  PubMed  CAS  Google Scholar 

  67. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009;22:76–98.

    Article  PubMed  CAS  Google Scholar 

  68. Sund F, Lidehall AK, Claesson K, et al. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study. Clin Transplant. 2010;24:401–9.

    Article  PubMed  Google Scholar 

  69. Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation. 1994;58:1176–8.

    PubMed  CAS  Google Scholar 

  70. •Griffiths PD, Stanton A, McCarrell E, et al.: Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256–1263. First randomized trial of a CMV vaccine given pre-SOT showing reduction in duration of CMV viremia and ganciclovir use post-transplant in D+/R- vaccinees

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tracy L. Lemonovich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lemonovich, T.L., Watkins, R.R. Update on Cytomegalovirus Infections of the Gastrointestinal System in Solid Organ Transplant Recipients. Curr Infect Dis Rep 14, 33–40 (2012). https://doi.org/10.1007/s11908-011-0224-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-011-0224-6

Keywords

Navigation